Home » Health » Moderna closes higher after research into effectiveness

Moderna closes higher after research into effectiveness

Wall Street stayed close to home. Moderna gained ground after a study showed that the pharmaceutical company’s vaccine works better than Pfizer’s. Campbell poured hot soup.

The US stock markets closed mixed. The Dow Jones

was down 0.1 percent, the S&P 500 kicked on the spot and the Nasdaq was up 0.3 percent.

There was less good news on the economic front. The US private sector created 374,000 jobs in August, up from 326,000 in July. That is a setback, because economists had predicted 625,000 extra jobs. The Ministry of Labor will publish the ‘official’ job report from August on Friday, which also takes into account government employment. If the labor market recovery continues, the US central bank will reduce its bond purchases later this year.

Modern

The share of Moderna

climbed 3.5 percent. This seems to have to do with a comparative study of the vaccines from Moderna and Pfizer, in which 2,499 Belgian health workers took part. This would show that Moderna’s vaccine works better than Pfizer’s.

The study was published Monday in the Journal of the American Medical Association. The health professionals surveyed had all received two vaccinations. This showed that the Moderna vaccine created more antibodies in the subjects studied than Pfizer’s drug. In addition, the study found that the antibodies were most prevalent in workers under the age of 35. “The higher mRNA content in the Moderna vaccine and the larger interval between the first and second vaccination may explain the difference,” it says.

Campbell Soup

Food company Campbell Soup climbed more than 2 percent. Organic net sales declined 4% in the three months to the end of July to $1.873 billion. The lower turnover was mainly due to the difficult basis for comparison. A year earlier – in the middle of the corona crisis – the company saw a lot of restocking at stores as consumers bought more food for home consumption. Compared to the same period in 2019, there was growth of 9 percent.



The fourth quarter was a positive end to a strong year in which we operated successfully in a difficult environment.

Mark Clouse

CEO van Campbell Soup



Revenue was above analysts’ expectations. Just like the profit, which was 8 cents higher than expected at 0.55 dollar. “The fourth quarter was a positive end to a strong year in which we operated successfully in a challenging environment,” said CEO Mark Clouse.

For the fiscal year 2022, the company foresees a turnover that will remain flat or slightly decrease. In addition, the group will buy up its own shares for 500 million dollars. That comes on top of the $250 million plan the company announced in the previous quarter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.